A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Public ClinicalTrials.gov record NCT03118570. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)
Study identification
- NCT ID
- NCT03118570
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Enrollment
- 112 participants
Conditions and interventions
Conditions
Interventions
- setrusumab Drug
- Calcium Dietary Supplement
- Vitamin D Dietary Supplement
- zoledronic acid (optional) Drug
Drug · Dietary Supplement
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 10, 2017
- Primary completion
- Sep 30, 2019
- Completion
- Nov 11, 2020
- Last update posted
- Jul 4, 2023
2017 – 2020
United States locations
- U.S. sites
- 12
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mereo Investigator Site | Birmingham | Alabama | 35294 | — |
| Mereo Investigator Site | Jacksonville | Florida | 32207 | — |
| Mereo Investigator Site | Baltimore | Maryland | 21287 | — |
| Mereo Investigator Site | Boston | Massachusetts | 012115 | — |
| Mereo Investigator Site | Saint Paul | Minnesota | 55101 | — |
| Mereo Investigator Site | St Louis | Missouri | 63110 | — |
| Mereo Investigator Site | Albuquerque | New Mexico | 87106 | — |
| Mereo Investigator Site | Cincinnati | Ohio | 45229 | — |
| Mereo Investigator Site | Portland | Oregon | 97239 | — |
| Mereo Investigator Site | Pittsburgh | Pennsylvania | 15225 | — |
| Mereo Investigator Site | Nashville | Tennessee | 37232 | — |
| Mereo Investigator Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03118570, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 4, 2023 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03118570 live on ClinicalTrials.gov.